Provide immunologic rationale for IL23 directed therapy in IBD

Sarah Enslin, PA-C, from the University of Rochester Medical Center, explains the role of IL-23 in driving inflammation in IBD and how IL-23-directed therapies like Guselkumab target this pathway. Learn how this selective inhibition reduces inflammation while preserving essential immune functions, improving patient outcomes in Crohn's disease and ulcerative colitis.